Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid.
Phenolic compounds are numerous and ubiquitous in the plant kingdom, being particularly present in health-promoting foods. Epidemiological evidences suggest that the consumption of polyphenol-rich foods reduces the incidence of cancer, coronary heart disease and inflammation. Chlorogenic acid (CGA) is one of the most abundant polyphenol compounds in human diet. Data obtained from in vivo and in vitro experiments show that CGA mostly presents antioxidant and anti-carcinogenic activities. However, the effects of CGA on the inflammatory reaction and on the related pain and fever processes have been explored less so far. Therefore, this study was designed to evaluate the anti-inflammatory, antinociceptive and antipyretic activities of CGA in rats. In comparison to control, CGA at doses 50 and 100 mg/kg inhibited carrageenin-induced paw edema beginning at the 2nd hour of the experimental procedure. Furthermore, at doses 50 and 100 mg/kg CGA also inhibited the number of flinches in the late phase of formalin-induced pain test. Such activities may be derived from the inhibitory action of CGA in the peripheral synthesis/release of inflammatory mediators involved in these responses. On the other hand, even at the highest tested dose (200 mg/kg), CGA did not inhibit the febrile response induced by lipopolysaccharide (LPS) in rats. Additional experiments are necessary in order to clarify the true target for the anti-inflammatory and analgesic effects of CGA.
dos Santos
Michel David
MD
University of São Paulo, Faculty of Pharmaceutical Sciences of Ribeirão Preto, Brazil.
Almeida
Maria Camila
MC
Lopes
Norberto Peporine
NP
de Souza
Glória Emília Petto
GE
D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D002351:Carrageenan / Q000008:administration & dosage / Q000633:toxicity; D002726:Chlorogenic Acid / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D005334:Fever / Q000139:chemically induced / Q000517:prevention & control; D005419:Flavonoids / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D005557:Formaldehyde / Q000008:administration & dosage / Q000633:toxicity; D006614:Hindlimb / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D007249:Inflammation / Q000139:chemically induced / Q000517:prevention & control; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000633:toxicity; D008297:Male; D015394:Molecular Structure; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control; D010636:Phenols / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D059808:Polyphenols; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000700:Analgesics; D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005419:Flavonoids; D008070:Lipopolysaccharides; D010636:Phenols; D059808:Polyphenols; D005557:Formaldehyde; D002726:Chlorogenic Acid; D002351:Carrageenan